Tuesday, July 16, 2019
Home Innovation That Matters

Innovation That Matters

MEI’s Oncology Programs Aim New Drug Development at Specific Genetic Targets with Breakthrough Potential

MEI Pharma is developing a new kind of small molecule epigenetic modifier in partnership with The Helsinn Group to treat acute myeloid leukemia (AML), a blood cancer that strikes mostly adults in their late 60s and leaves some patients with limited options for survival. The...

GENFIT Seeking Breakthrough Therapies for Little-Known but Severe Liver Diseases to make a Real Difference in Patients’ Lives

Non-alcoholic steatohepatitis or NASH and biliary cholangitis or PBC are two very serious liver diseases affecting millions of people, but with no known cures or effective therapies. The difficult and unsuccessful search so far for breakthrough remedies for these diseases has not deterred the...

A Conversation with Richard Lerner: DELopen Promotes Worldwide Academic Research Using DNA-Encoded Libraries, Far More Than Just a Numbers Game

By Rich Soll (Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx). Richard Lerner is a visionary.  He and Sydney Brenner, both of the Scripps Research Institute (Scripps) first published on DNA-encoded libraries (DELs) in 1992 in the Proceedings of the National Academy of Sciences.  Yet it...

Enabling Synthetic and Medicinal Chemists with the Predictive Power of Quantum Mechanics

By Rich Soll (Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx). A key rate-limiting step in the discovery of drugs is the synthesis of target molecules:  multistep, many times low yielding, many times taking weeks to prepare a single molecule. Often, side reactions result in unanticipated...

At the Cutting Edge of R&D Enablement, the Virtual Korean Biotech Bridge Biotherapeutics Builds a Pipeline of First- and Best-In-Class Therapeutics

By Rich Soll Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) and the WuXi Content Team Founded only in 2015 and currently running with merely 17 members, South Korea-based Bridge Biotherapeutics has brought two molecular compounds forward to early clinical stages, with more programs being generated in its...




Twitter LinkedIn